iJournal Club - Lung Cancer: 2013
OVERVIEW OF ACTIVITY
Lung cancer is a devastating disease with broad-reaching impact on public health as it accounts for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In 2013, it is estimated that 228,190 new cases will be diagnosed and 159,480 deaths will occur from the disease. In addition, only 16% of all patients with lung cancer are alive 5 years or more after diagnosis, despite currently available therapies.
iJournal Club - Lung Cancer: 2013
Breast Cancer Update for Surgeons, Issue 1
OVERVIEW OF ACTIVITY
iJournal Club - Lung Cancer: 2013
Results from 2 Phase III studies with maintenance pemetrexed and/or bevacizumab in patients with advanced nonsquamous NSCLC
Zinner R et al. Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). Proc ASCO 2013;Abstract LBA8003.
Meet The Professors: Clinical Investigators Provide Their Perspectives on Real Cases of Metastatic Breast Cancer
Meet The Professors: Clinical Investigators Provide Their Perspectives on Real Cases of Metastatic Breast Cancer
TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists and other healthcare providers involved in the treatment of breast cancer.
Clone of Consensus or Controversy, Issue 2: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Myelofibrosis
Beyond the Guidelines: Assessing the Treatment Recommendations of Investigators to Assist in the Practical Management of Multiple Myeloma and Non-Hodgkin Lymphoma
Beyond the Guidelines: Assessing the Treatment Recommendations of Investigators to Assist in the Practical Management of Multiple Myeloma and Non-Hodgkin Lymphoma
TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of hematologic cancer.
Second Opinion: Proceedings from an Interactive Case-Based Symposium on the Management of Patients with Metastatic Colorectal Cancer
Challenging Cases in Multiple Myeloma: Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty
Challenging Cases in Breast Cancer: Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty
Challenging Cases in Lung Cancer: Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty
Challenging Cases in Non-Hodgkin Lymphoma: Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty
Second Opinion: Proceedings from an Interactive Case-Based Symposium on the Management of Patients with Metastatic Colorectal Cancer
TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, gastrointestinal surgeons and other healthcare providers involved in the treatment of colorectal cancer (CRC).